Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
For the treatment of mature B cell malignancies including chronic lymphocytic leukemia (CLL), the last 5 years has brought major advances in the application of targeted therapies. Whilst monoclonal anti-CD20 agents such as rituximab have a central role in combination with traditional cytotoxic thera...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publishing
2019-05-01
|
| シリーズ: | Therapeutic Advances in Hematology |
| オンライン･アクセス: | https://doi.org/10.1177/2040620719844697 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|